Dr Laura Kenny is a Consultant in Medical Oncology specialising in breast cancer. She trained in medicine at Queen's University Belfast and, after completing initial registrar training, moved to London to study for a PhD in translational molecular imaging at the Cyclotron Building, Imperial College London. Her clinical practice is based at Charing Cross and Hammersmith Hospitals. In addition, Dr Kenny is a Clinical Senior Lecturer at Imperial College. Dr Kenny was awarded a Westminster Medical School Oncology Trustee's fellowship, and her research has focused on the use of novel PET radiotracers for studying proliferation, angiogenesis, and choline metabolism in breast cancer patients. Her work has been published in Cancer Research, Clinical Cancer Research, the Journal of Nuclear Medicine, and the European Journal of Molecular Imaging and Nuclear Medicine. She was awarded a prestigious NIHR/MRC clinician scientist fellowship in 2010, aiming to establish new methods for defining the imaging phenotype in patients, helping to predict drug resistance and drug sensitivity at early time points to established and novel cancer therapeutic agents. Dr Kenny was also appointed as Director of Early Phase Clinical Trials in Cancer, aiming to expedite clinical drug development with novel approaches to clinical trials. She was awarded an MRC DPFS project grant to study a new Affibody probe targeting her2 expression in breast cancer. Her areas of expertise include chemotherapy and breast cancer.